Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
John P. Veluchamy(Cancer Center Amsterdam), Daniëlle A.M. Heideman(University Medical Center Groningen), Victor L. Thijssen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Tanja D. de Gruijl(Dutch Cancer Society), Marleen Tordoir(Radboud University Nijmegen), Henk M.W. Verheul(Erasmus MC Cancer Institute), Jan Spanholtz(AIMM Therapeutics (Netherlands))
Cited by 85
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|582
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
|Nature reviews. Cancer|2007|502